中文产业新闻评分33Chinese source
Amgen启动maridebart cafraglutide针对2型糖尿病/肥胖/超重的Ⅲ期临床试验
10月魔方TOP药企动态播报 | Amgen-maridebart cafraglutide启动一项 针对2型糖尿病,肥胖,超重的Phase III临床试验
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.